Risk of paediatric multisystem inflammatory syndrome (PIMS-TS) during the SARS-CoV-2 alpha and delta variant waves: National observational and modelling study, 2020–21, England

Shingleton, Joseph; Burton, Lucy; Williams, Hannah; Finnie, Thomas; Bennett, Emma; Birrell, Paul; Kenny, Simon; Watson-Koszel, Tiffany; Viner, Russell; Arditi, Moshe; DeAngelis, Daniela; Gent, Nick; Ladhani, Shamez

doi:10.3389/fped.2022.1034280

Cited by 7 publications

(2 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MIS-C appears to be a relatively rare complication of COVID-19 in children, with an incidence that was initially estimated to be between 54 and 45 cases/100,000 SARS-CoV-2 infections in children < 15 years old [ 44 , 45 ]. Since the first descriptions, the incidence of MIS-C has been decreasing over time [ 15 ].…”

Section: How Common Is Mis-c and Is Mis-c Incidence Decreasing Throug...mentioning

confidence: 99%

Multi-Inflammatory Syndrome in Children (MIS-C) in 2023: Is It Time to Forget about It?

et al. 2023

View full text Add to dashboard Cite

Multisystem inflammatory syndrome in children (MIS-C) is defined as a clinically serious condition requiring hospitalization involving fever, multi-system organ dysfunction, and an increase in inflammatory biomarkers. The syndrome was originally described as a post-infectious complication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, which usually causes COVID-19. During the COVID-19 pandemic, not only did the virus undergo mutations but vaccines against SARS-CoV-2 were also developed. Both these conditions led to a decrease in the incidence of MIS-C. This narrative review summarizes the recent updates for MIS-C, particularly regarding the change in incidence, the link between the SARS-CoV-2 vaccine and MIS-C, and new updates of MIS-C treatments.

show abstract

Section: How Common Is Mis-c and Is Mis-c Incidence Decreasing Throug...mentioning

confidence: 99%

Multi-Inflammatory Syndrome in Children (MIS-C) in 2023: Is It Time to Forget about It?

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Paediatric Multisystem Inflammatory Syndrome temporally associated with SARS-CoV-2 (PIMS-TS) is a life-threatening complication that typically occurs around two to six weeks after SARS-CoV-2 infection in children and young people [ 1 ]. The disease was described during the first wave of the COVID-19 pandemic, in 2020 [ 2 , 3 ].…”

Section: Introductionmentioning

confidence: 99%

Programmed Cell Death Protein-1 Regulation in Response to SARS-CoV-2 in Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2: A Prospective Cohort Study

Opoka-Winiarska,

Grywalska,

Morawska-Michalska

et al. 2024

IJMS

View full text Add to dashboard Cite

The role of programmed death cell protein 1 (PD-1) has already been described in a range of various diseases, including COVID-19. This study provides new, innovative data, related to the expression of PD-1 and the risk of Paediatric Inflammatory Multisystem Syndrome, temporally associated with SARS-CoV-2 infection (PIMS-TS)—a rare, but potentially life-threatening complication of COVID-19. In this study, we evaluated the expression of PD-1 protein in patients with PIMS. Blood samples were taken from patients at the time of diagnosis (n = 33), after 6 weeks (n = 33), 3 months (n = 24), 6 months (n = 24) and 12 months (n = 8). The immunophenotypes were evaluated in flow cytometry. The control group consisted of 35 healthy children with negative SARS-CoV-2 antigen/PCR test, who were asymptomatic and had no history of allergic, autoimmune or oncological diseases. The associations between immunophenotypes, biochemical findings and clinical data were analysed. Significant increases in the expression of PD-1 for CD4+ and CD8+ T cells, compared to the control group, were observed in the day of admission, with a gradual decrease during the first weeks from initiation of treatment. This study sheds new light on the pathogenesis of PIMS-TS, emphasizing the role of PD-1 protein. Future research is essential for early risk prediction in SARS-CoV-2 patients and for devising effective clinical prevention and management strategies.

show abstract

The changing epidemiology of PIMS-TS across COVID-19 waves: prospective national surveillance, January 2021 to July 2022, England

Shingleton¹,

Williams²,

Oligbu³

et al. 2022

Journal of Infection

View full text Add to dashboard Cite

Risk of paediatric multisystem inflammatory syndrome (PIMS-TS) during the SARS-CoV-2 alpha and delta variant waves: National observational and modelling study, 2020–21, England

Cited by 7 publications

References 54 publications

Multi-Inflammatory Syndrome in Children (MIS-C) in 2023: Is It Time to Forget about It?

Multi-Inflammatory Syndrome in Children (MIS-C) in 2023: Is It Time to Forget about It?

Programmed Cell Death Protein-1 Regulation in Response to SARS-CoV-2 in Paediatric Multisystem Inflammatory Syndrome Temporally Associated with SARS-CoV-2: A Prospective Cohort Study

The changing epidemiology of PIMS-TS across COVID-19 waves: prospective national surveillance, January 2021 to July 2022, England

Contact Info

Product

Resources

About